Double mutant and formaldehyde inactivated TSST-1 as vaccine
candidates

J 2002

Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates

GAMPFER, J., Vojtěch THON, H. GULLE, Hermann WOLF, Marta EIBL et. al.

Basic information

Original name

Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates

Name in Czech

Inaktivované TSST-1 jako kandidátní vakcíny pro syndrom tox. šoku

Authors

GAMPFER, J. (276 Germany), Vojtěch THON (203 Czech Republic, guarantor), H. GULLE (40 Austria), Hermann WOLF (40 Austria) and Marta EIBL (40 Austria)

Edition

Vaccine, 2002, 0264-410X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30102 Immunology

Country of publisher

United Kingdom of Great Britain and Northern Ireland

Confidentiality degree

není předmětem státního či obchodního tajemství

Impact factor

Impact factor: 2.811

RIV identification code

RIV/00216224:14110/02:00030462

Organization unit

Faculty of Medicine

UT WoS

000173858300010

Keywords (in Czech)

TSST-1 vakcína

Keywords in English

TSST-1 vaccine

Abstract

ORIG CZ

V originále

Up to now there is no treatment for staphylococcal toxic shock syndrome, a disease mainly induced by toxic shock syndrome toxin-1(TSST-1). There is great demand in finding means to control the disease, one of them is the development of an effective and safe vaccine against TSST-1. In this study we constructed a series of vaccine candidates and investigated their biological activity, toxicity, and potential to invoke an immune response. TSST-1 was isolated from Stahylococcus aureus supernatants and recombinantly expressed as a N-terminal 6x histidine-tagged protein in Escherichia coli. In order to obtain molecules with minimal toxicity we constructed single mutants (G31R and H135A) and one double mutant (G31R/H135A) with both residues exchanged. We also detoxified native TSST-1 isolated from S. aureus, and recombinantly expressed TSST-1 by treatment with formaldehyde. Functional activity of native and recombinant TSST-1 and grade of inocuity of mutants and toxoids was determined by investigating mitogenity, T-cell activation, and cytokine release upon stimulation of human mononuclear cells with the vaccine candidates. All substances were tested in a rabbit immunization study. After primary immunization and three additional boosts all vaccinated animals developed antibody titers against TSST-1 and were protected against challenge with a lethal doses of superantigen potentiated with lipopolysaccharide.

In Czech

Inaktivované TSST-1 jako kandidátní vakcíny pro syndrom toxického šoku.

Citovat

GAMPFER, J., Vojtěch THON, H. GULLE, Hermann WOLF and Marta EIBL. Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates. Vaccine. 2002, vol. 20, 9-10, p. 1354-64, 11 pp. ISSN 0264-410X.

@article{397102,
   author = {Gampfer, J. and Thon, Vojtěch and Gulle, H. and Wolf, Hermann and Eibl, Marta},
   article_number = {9-10},
   keywords = {TSST-1 vaccine},
   language = {eng},
   issn = {0264-410X},
   journal = {Vaccine},
   title = {Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates},
   volume = {20},
   year = {2002}
}

TY  - JOUR
ID  - 397102
AU  - Gampfer, J. - Thon, Vojtěch - Gulle, H. - Wolf, Hermann - Eibl, Marta
PY  - 2002
TI  - Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates
JF  - Vaccine
VL  - 20
IS  - 9-10
SP  - 1354-64
EP  - 1354-64
SN  - 0264410X
KW  - TSST-1 vaccine
N2  - Up to now there is no treatment for staphylococcal toxic shock syndrome, a disease mainly induced by toxic shock syndrome toxin-1(TSST-1). There is great demand in finding means to control the disease, one of them is the development of an effective and safe vaccine against TSST-1. In this study we constructed a series of vaccine candidates and investigated their biological activity, toxicity, and potential to invoke an immune response. TSST-1 was isolated from Stahylococcus aureus supernatants and recombinantly expressed as a N-terminal 6x histidine-tagged protein in Escherichia coli. In order to obtain molecules with minimal toxicity we constructed single mutants (G31R and H135A) and one double mutant (G31R/H135A) with both residues exchanged. We also detoxified native TSST-1 isolated from S. aureus, and recombinantly expressed TSST-1 by treatment with formaldehyde. Functional activity of native and recombinant TSST-1 and grade of inocuity of mutants and toxoids was determined by investigating mitogenity, T-cell activation, and cytokine release upon stimulation of human mononuclear cells with the vaccine candidates. All substances were tested in a rabbit immunization study. After primary immunization and three additional boosts all vaccinated animals developed antibody titers against TSST-1 and were protected against challenge with a lethal doses of superantigen potentiated with lipopolysaccharide.
ER  -

GAMPFER, J., Vojtěch THON, H. GULLE, Hermann WOLF and Marta EIBL. Double mutant and formaldehyde inactivated TSST-1 as vaccine candidates. \textit{Vaccine}. 2002, vol.~20, 9-10, p.~1354-64, 11 pp. ISSN~0264-410X.

Detailed Information on Publication Record